we heal CHRONIC WOUNDS

WE DON'T JUST TREAT THEM

Breakthroughs aren't incremental. Our new approach to chronic wound healing moves far beyond symptom treatment.

Incremental improvement to chronic wound treatment is insufficient. Each year, thousands of patients undergo preventable amputations as a result of ineffective management of Diabetic Foot Ulcer or Venous Leg Ulcer; others suffer from psychological, physical burden and decreased quality of life due to pressure ulcers.

BURDEN OF CHRONIC WOUNDS

Burden of chronic wounds
Burden of chronic wounds

aup-16: our lead clinical asset for chronic wounds

a world first 4-in-1 cell therapy

We believe that, when treating chronic wounds, one needs to hit multiple targets to be disease-modifying. Very few companies or products can claim to truly target multiple biological targets. Carefully designed and developed pharmaceutical products, such as our Advanced Therapy Medicinal Product (ATMP) AUP-16, will make the difference. Our new ATMP approach promotes the healing of the wound by promoting tissue regeneration and releasing active biological therapeutic agents within the wound itself.

AUREALIS THERAPEUTICS 4-IN-1 PRODUCT AUP-16

One Active Pharmaceutical Ingredient (API) product with the benefits of four therapeutics.

AUP-16 is a safe and effective recombinant live biotherapeutic product that features a patented active bacterial vector. AUP-16 includes four therapies in one product:

1. LACTOCOCCUS
LACTIS

A non-pathogenic bacteria that acts as a bioreactor in the tissue, producing human therapeutic proteins in the wound. AUP-16 takes advantage of the safe, living bioreactor to produce proteins FGF-2, IL-4 and CSF-1.

2. FIBROBLAST GROWTH FACTOR (FGF-2)

A clinically used growth factor and signaling protein involved in cell proliferation and tissue repair.

3. INTERLEUKIN 4
(IL-4)

A potent anti-inflammatory M2 cytokine that promotes regeneration.

4. COLONY STIMULATING
FACTOR 1 (CSF-1)

A hematopoietic growth factor involved in the proliferation, differentiation, and survival of monocytes, macrophages, and bone marrow progenitor cells.

AUP-16 is a topical treatment created using a genetically modified lactococcus lactis bacteria. AUP-16 promotes healing by producing three therapeutic human proteins that (1) improve cell activation and conversion to anti-inflammatory phenotype, (2) increase fibroblast proliferation, and (3) promote angiogenesis and granulation tissue formation. 

The continuous production of the three therapeutic proteins FGF-2, IL-4 and CSF-1 by the active vector lactococcus lactis at the site of the wound, results in our unique 4-in-1 combination biological treatment which is provided as one API.

Aurealis Therapeutics AUP-16

AUP-16 provides multi-therapy in one product, it is not a combination product. Thanks to its multi-therapy approach, AUP-16 is able to reduce inflammation promote proliferation and angiogenesis, and accelerate remodeling.  All in one product.

Our therapy, AUP-16, is created under Good Manufacturing Practice conditions and analyzed using state-of-the-art methods to ensure identity, potency, consistency, and safety. 

AUP-16 has the power to accelerate and provide complete wound healing, avoiding amputations. This remarkable advancement is ideal for patients who only achieve partial response to wound care dressings and treatment of symptoms.

As opposed to the existing standard of care, AUP-16 promotes tissue regeneration in the wound to activate healing from within.

HIGHLIGHTS OF AUP-16

HIGHLIGHTS OF AUP-16

FOUR-IN-ONE

cell therapy stimulates endogenous tissue regeneration

BIOAVAILABLE

protein production at the site of injury

TOPICAL APPLICATION

makes it easy to  administer

SAFE

modified food-grade bacteria

WATCH AUP-16 MODE OF ACTION VIDEO

READ OUR SCIENTIFIC PUBLICATIONS ABOUT AUP-16

2018:
Aurealis EWMA Poster
Therapeutic use of Lactococcus lactis for wound healing

2022:
4-in-1 Combination therapy using Lactococcus lactis expressing three therapeutic proteins for the treatment of chronic non healing wounds

OUR OUTCOME WITH AUP-16 AND CHRONIC WOUNDS

CLINICAL TRIALS

AUP-16: PHASE 1 CLINICAL STUDY

83% of patients reached complete healing
no recurrEnce during 3 months follow-up

In June 2022, we successfully completed the Phase 1 study in non-healing Diabetic Foot Ulcer patients with our lead product AUP-16. While patient observation continues, collected data will be processed and consolidated for publication.

Aurealis Therapeutics technology platform works in real life: non-healing diabetic wounds heal. Clinical results: 83% of patients reached complete healing.

More details about our Phase 1 Clinical Study:
NIH National Library of Medicine record

More details about our Phase 1 Clinical Study:
EU Clinical Trials Register

AUP-16: PHASE 2 CLINICAL STUDIES

Aurealis Therapeutics Chronic Wounds

DIABETIC FOOT ULCER l VENOUS LEG l PRESSURE ULCER

We are about to start our Phase 2 clinical study in Diabetic Foot Ulcers. Clinical centers are being recruited in Italy, Germany and Poland.

Phase 2 Venous Leg Ulcer and Pressure Ulcer will follow.

CHRONIC WOUNDS: AUP-16

Aurealis Therapeutics Pipeline Chronic Wounds

Do you want to knoW more about our lead asset aup-16?